Overview The Efficacy of WVI in Patients With Localized Basal Ganglia Intracranial Germ Cell Tumors Status: Recruiting Trial end date: 2026-10-31 Target enrollment: Participant gender: Summary Primary endpoint 1. three-year disease-free survival of patients with localized basal ganglia germ cell tumors receiving whole-ventricle irradiation 2. Health-related quality of life measured by PedsQL 4.0 and SF-36 Second endpoint 1. three-year overall survival of patients with localized basal ganglia germ cell tumors receiving whole-ventricle irradiation 2. Adverse effects of chemoradiotherapy measured by NCI CTCAE 5.0 Phase: Phase 2 Details Lead Sponsor: Beijing Tiantan HospitalTreatments: CarboplatinEtoposideEtoposide phosphateIfosfamide